fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study in kidney transplant patients – Hansa Biopharma

Written by | 20 Oct 2023

Hansa Biopharma announced results from an extended pooled analysis using data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant… read more.

Update on ConfIdeS phase III trial of imlifidase in highly sensitized kidney transplant patients – Hansa Biopharma

Written by | 17 Oct 2023

Hansa Biopharma announced randomization for the US ConfIdeS trial is expected to conclude in mid-2024. The ConfIdeS trial is an open-label, controlled, randomized Phase III trial evaluating 12-month… read more.

Positive early access decision by French Haute Autorité de Santé to use Idefirix as desensitization treatment for highly sensitized kidney transplant patients – Hansa Biopharma AB

Written by | 21 Mar 2022

Hansa Biopharma AB, the pioneer in enzyme technology for rare immunological conditions, announced that its first-in-class treatment Idefirix (imlifidase) has been granted early access post marketing authorization (Autorisation… read more.

Hansa Biopharma announces long term follow-up data demonstrating 3-year graft survival of 84% after imlifidase treatment and transplantation

Written by | 13 Jul 2021

Hansa Biopharma, announced three-year follow-up data in crossmatch positive patients who received imlifidase prior to kidney transplantation. As reported in an article, which has been accepted for publication… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.